Patents by Inventor Kevin McGrath
Kevin McGrath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951253Abstract: A positive exhalation pressure device (1) is described. The device (1) comprises a housing (2) having an annular chamber (5), a chamber inlet (6) configured to permit air into the chamber, a chamber outlet (7) configured to permit air out of the chamber, and a mouthpiece (8) in fluid communication with the chamber inlet. A movable body such as a ball (3) is disposed in the housing within the annular chamber and configured to revolve around the annular chamber in response to flow of air through the chamber from the chamber inlet to the chamber outlet. The movable body is configured to at least partially block the chamber outlet as it revolves around the annular chamber causing cyclical fluctuations in airflow resistance.Type: GrantFiled: September 15, 2020Date of Patent: April 9, 2024Assignee: Solopep LimitedInventors: Kevin J. O'Sullivan, Leonard W. O'Sullivan, Colum Dunne, Barry Linnane, Deirdre McGrath
-
Patent number: 11945830Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: February 24, 2022Date of Patent: April 2, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Adam Szymaniak, Jianming Yu, Kevin McGrath, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen
-
Patent number: 11945824Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: October 18, 2021Date of Patent: April 2, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Yong He, Kevin McGrath, Ruichao Shen, Adam Szymaniak, Xuechao Xing, In Jong Kim, Guoqiang Wang
-
Patent number: 11915053Abstract: Systems, methods, and machine-readable media for predicting interruptions to the use of spare cloud resources and rebalancing based on those predictions are disclosed. A computing platform collects data for customers over time. The computing platform runs a machine learning algorithm on the historical data to generate a prediction classifier. The prediction classifier relates to a time window for prediction into the future, on the order of minutes or hours. The prediction classifier is run on monitored data from ongoing activity with a cloud provider to generate a risk score. Each risk score may identify an amount of risk that a spare cloud resource related to new resource metrics data will be interrupted within the future time frame corresponding to that prediction classifier. If predicted to be interrupted, the customer may be assisted in rebalancing to other resources. As a result, interruptions can be predicted hours into the future.Type: GrantFiled: March 19, 2021Date of Patent: February 27, 2024Assignee: NETAPP, INC.Inventors: Idan Schwartz, Ohad Muchnik, Jonathan Cohen, Kevin McGrath, Amiram Shachar
-
Patent number: 11912695Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: January 13, 2022Date of Patent: February 27, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
-
Publication number: 20230357258Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 6, 2023Publication date: November 9, 2023Inventors: Adam Szymaniak, Robert Leon, Kevin McGrath, Xiben Li, Tyler J. Mann, Jianming Yu, In Jong Kim, Scott Mitchell, Yat Sun Or
-
Publication number: 20230125803Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: August 24, 2022Publication date: April 27, 2023Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
-
Publication number: 20230115580Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 13, 2022Publication date: April 13, 2023Inventors: Adam Szymaniak, Jianming Yu, Kevin McGrath, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen
-
Publication number: 20230108803Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: February 24, 2022Publication date: April 6, 2023Inventors: Adam Szymaniak, Jianming Yu, Kevin McGRATH, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen
-
Patent number: 11572367Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: July 16, 2020Date of Patent: February 7, 2023Assignee: Enanta Pharmaceuticals, Inc.Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
-
Patent number: 11505558Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: April 1, 2021Date of Patent: November 22, 2022Assignee: Enanta Pharmaceuticals, Inc.Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
-
Publication number: 20220356189Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: July 16, 2020Publication date: November 10, 2022Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
-
Publication number: 20220227746Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: January 13, 2022Publication date: July 21, 2022Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
-
Publication number: 20220129322Abstract: Systems, methods, and machine-readable media for predicting interruptions to the use of spare cloud resources and rebalancing based on those predictions are disclosed. A computing platform collects data for customers over time. The computing platform runs a machine learning algorithm on the historical data to generate a prediction classifier. The prediction classifier relates to a time window for prediction into the future, on the order of minutes or hours. The prediction classifier is run on monitored data from ongoing activity with a cloud provider to generate a risk score. Each risk score may identify an amount of risk that a spare cloud resource related to new resource metrics data will be interrupted within the future time frame corresponding to that prediction classifier. If predicted to be interrupted, the customer may be assisted in rebalancing to other resources. As a result, interruptions can be predicted hours into the future.Type: ApplicationFiled: March 19, 2021Publication date: April 28, 2022Inventors: Idan Schwartz, Ohad Muchnik, Jonathan Cohen, Kevin McGrath, Amiram Shachar
-
Publication number: 20220119398Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 18, 2021Publication date: April 21, 2022Inventors: Yat Sun Or, Yong He, Kevin McGrath, Ruichao Shen, Adam Szymaniak, Xuechao Xing, In Jong Kim, Guoqiang Wang
-
Patent number: 11254664Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: March 17, 2020Date of Patent: February 22, 2022Assignee: Enanta Pharmaceuticals, Inc.Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
-
Patent number: 11091501Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: June 29, 2018Date of Patent: August 17, 2021Assignee: Enanta Pharmaceuticals, Inc.Inventors: In Jong Kim, Jianming Yu, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Thomas P. Blaisdell, Brian C. Shook, Yat Sun Or
-
Publication number: 20200299286Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: March 17, 2020Publication date: September 24, 2020Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
-
Patent number: 10759816Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: August 10, 2018Date of Patent: September 1, 2020Assignee: Enanta Pharmaceuticals, Inc.Inventors: Jianming Yu, Brian C. Shook, Thomas P. Blaisdell, In Jong Kim, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Yat Sun Or
-
Publication number: 20190040084Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: August 10, 2018Publication date: February 7, 2019Inventors: Jianming Yu, Brian C. Shook, Thomas P. Blaisdell, In Jong Kim, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Yat Sun Or